Table 1 Baseline characteristics of the study cohort

Baseline characteristics

 Age, years

58.53 ± 8.23

55.55 ± 11.8

61.54 ± 9.11

 Male, n (%)

27 (48.2%)

48 (30.7%)

28 (60.8%)^§

 BMI, kg/m²

23.17 ± 3.14

23.67 ± 3.06

25.32 ± 3.35

 Systolic blood pressure, mmHg

120.19 ± 8.85

127.96 ± 13.11

123.67 ± 19.27

 Diastolic blood pressure, mmHg

75.73 ± 10.36

79.88 ± 9.88

77.89 ± 12.76

 Heart rate, bpm

73.28 ± 10.85

72.67 ± 15.42

73.80 ± 14.60

Cardiovascular risk factors

 Previous/current smoker, n (%)

9 (15.2%)

44 (28.3%)

23 (50.5%)^§

 Hyperlipidemia

0

29 (18.5%)

8 (17.4%)

 Family history of DM

0

32 (20.5%)

11 (23.9%)

 Pervious PCI, n (%)

0

0

20 (43.5) %

 Previous CABG, n (%)

0

0

1 (2.2%)

NYHA functional class, n

 I

–

–

3 (6.5%)

 II

–

–

27 (58.7%)

 III

–

–

15 (32.6%)

 IV

–

–

1 (2.2%)

Culprit vessel n (%)

 LM

–

–

0

 LAD

–

–

14 (30.43%)

 LCx

–

–

6 (13.0%)

 RCA

–

–

14 (30.43%)

Metabolic characteristics

 HbA1c, %

5.46 ± 0.34

7.82 ± 0.87

8.10 ± 1.32

 Fasting plasma glucose, mmol/L

5.08 ± 0.45

8.28 ± 1.23

8.78 ± 2.34

 eGFR, mL/min/1.73 m²

107.23 ± 8.45

95.84 ± 9.32

79.60 ± 10.45

 NT-proBNP

–

–

874 (204.75–2032.75)

Medication, n (%)

 Aspirin, n (%)

–

17 (6.5%)

28 (60.8%)

 ß-blockers, n (%)

–

0

11 (19.6%)

 ACEI/ARB, n (%)

–

5 (3.2%)

16 (34.7%)

 Diuretics

–

1 (0.06%)

13 (28.2%)

 Calcium-channel blocker

–

8 (5.1%)

5 (10.8%)

 Insulin

–

36 (23.1%)

7 (15.2%)

 Statin, n (%)

–

6 (3.8%)

14 (30.4%)